Pharmaceutical and Biotechnological Stocks

Biomerica set to release earnings this Friday – here’s what you need to know.

Biomerica (NASDAQ:BMRA) is set to release Q2 earnings this Friday, with experts forecasting an expected EPS of -$0.05. This would mark a 37% improvement for Q2 Earnings Year on Year. The medical diagnostic manufacturer has thrived on the opportunity this year to develop a viable COVID-19 test. Biomerica’s rapid COVID-19 test is marketed produce results …

Biomerica set to release earnings this Friday – here’s what you need to know. Read More »

Fluidigm soars 25% on COVID-19 FDA approval – here’s what you need to know

Fluidigm Corporation (NASDAQ: FLDM) just became a bull-market magnet as its COVID-19 saliva kit received FDA approval. Optimism is high in pre-market trading as some bullish investors believe this is news to send FLDM soaring. However, the bears are screaming that a pump and dump is coming at the bell. The division in sentiment causes …

Fluidigm soars 25% on COVID-19 FDA approval – here’s what you need to know Read More »

Johnson & Johnson set to acquire Momenta Pharmaceuticals – here’s what investors need to know

Johnson & Johnson announced this morning that they have entered a “definitive agreement” to acquire Momenta Pharmaceuticals at $52.50 per share. The acquisition has been confirmed as an all-cash transaction, which has been approved “unanimously” by the Board of Directors from both J&J and Momenta. The acquisition is set to be finalised later this year, …

Johnson & Johnson set to acquire Momenta Pharmaceuticals – here’s what investors need to know Read More »

CureVac the newest vaccine contender on Wallstreet – here’s everything you need to know

CureVac’s (NASDAQ:CVAC) initial public offering in the US markets went incredibly well for investors, posting a 250% gain on its first day of trading. CureVac is a German Biopharma, based in Tübingen who specialises in the development of vaccines for infectious diseases. CVAC’s IPO raised $213.3 million USD in funding at its short price of …

CureVac the newest vaccine contender on Wallstreet – here’s everything you need to know Read More »

U.S government orders 100 million doses of Moderna’s vaccine, yet insiders are selling – here’s what you need to know

Moderna (NASDAQ: MRNA), alongside Novavax, is running at full speed in the vaccine race. The Trump Administration’s recent agreement with Moderna to order 100 million doses adds to the argument that MRNA is at the front of the pack. While the announcement is a positive catalyst, investors are doubtful that we will see an enormous …

U.S government orders 100 million doses of Moderna’s vaccine, yet insiders are selling – here’s what you need to know Read More »

Here’s how much a $10,000 investment in this COVID-19 vaccine company is worth now

The COVID-19 vaccine industry has seen immense investor backing with popular US listed companies such as Moderna, Pfizer and Vaxart multiplying their pre-COVID value upwards of 500%-1,000%. However, Novavax, Inc. (NASDAQ: NVAX) has surpassed it’s rivals in stock value growth, currently priced at $143.10. An investment of $10,000 in NVAX after the initial COVID-19 vaccine …

Here’s how much a $10,000 investment in this COVID-19 vaccine company is worth now Read More »

BNGO rises 100% off COVID-19 DNA research – here’s what you need to know.

Binano Genomics (NASDAQ: BNGO) catapulted itself onto the COVID-19 stage this week, which naturally saw investors flood the market. The area that BNGO is targeting is the COVID research field. However, for most investors, the scientific jargon can make the task of understanding the company, let alone investing, extremely difficult. Thus, this article will provide …

BNGO rises 100% off COVID-19 DNA research – here’s what you need to know. Read More »

Actinium Pharmaceuticals hits 150% gain over 2 months – here’s everything you need to know

Actinium Pharmaceuticals (NYSE:ATNM) has caught the attention of investors as the stock continues its path of strong bullish momentum. ATNM is likely to open at $0.56 according to pre-market movements, marking a 211% gain over the past 2 months. The Bio-Pharma works on the development of commercial therapies for bone marrow transplant and other adoptive cell …

Actinium Pharmaceuticals hits 150% gain over 2 months – here’s everything you need to know Read More »

Moderna COVID-19 vaccine success – here’s everything you need to know.

Moderna (NASDAQ:MRNA) alongside the US National Institutes of Health have made a historic breakthrough in the race for a viable COVID-19 vaccine. MRNA’s results showed all 45 patients from the Phase 1 trial saw an induced anti-body production. This anti-body production simply put helps bolster the individuals immune response to the virus. The markets are expected …

Moderna COVID-19 vaccine success – here’s everything you need to know. Read More »

SRNE surges 20% off COVID-19 lawsuit – has news been leaked?

Sorrento Therapeutics’ (NASDAQ: SRNE) saying they have a COVID-19 treatment that offers a 100% protection, before conducting trials, was an incredibly bold statement. SRNE’s optimistic announcement not only lit the investment world alight but also pushed them into the legal spotlight. It is the possible lawsuit charges that caused the bears to multiply. However, SRNE …

SRNE surges 20% off COVID-19 lawsuit – has news been leaked? Read More »